{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T03:07:02Z","timestamp":1775617622081,"version":"3.50.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T00:00:00Z","timestamp":1595635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40256-020-00422-0","type":"journal-article","created":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T01:02:18Z","timestamp":1595638938000},"page":"165-180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3651-6848","authenticated-orcid":false,"given":"Vin\u00edcius Bocchino","family":"Seleme","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo Lenci","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Eduardo Matoso","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inajara","family":"Rotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milena","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilton Lima","family":"J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio L. Pereira","family":"da Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,25]]},"reference":[{"key":"422_CR1","first-page":"1","volume":"107","author":"MVB Malachias","year":"2016","unstructured":"Malachias MVB, Souza WKSB, Plavnik FL, Rodrigues CIS, Brand\u00e3o AA, Neves MFT, et al. 7th Brazilian guidelines of hypertension. Arq Bras Cardiol. 2016;107:1\u201383.","journal-title":"Arq Bras Cardiol"},{"key":"422_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5935\/abc.2013S012","volume":"101","author":"AF Sim\u00e3o","year":"2013","unstructured":"Sim\u00e3o AF, Sim\u00e3o AF, Precoma DB, Andrade JP, Correa FH, Saraiva JF, Sociedade Brasileira de Cardiologia, et al. Brazilian guideline for cardiovascular prevention [in Portuguese]. Arq Bras Cardiol. 2013;101:1\u201363.","journal-title":"Arq Bras Cardiol"},{"key":"422_CR3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC-8). JAMA. 2014;311:507\u201320.","journal-title":"JAMA"},{"key":"422_CR4","doi-asserted-by":"crossref","first-page":"85129","DOI":"10.1371\/journal.pone.0085129","volume":"9","author":"A Abdulle","year":"2014","unstructured":"Abdulle A, Al-Junaibi, Nagelkerke N. High blood pressure and its association with body weight among children and adolescents in the United Arab Emirates. PLoS One. 2014;9:85129.","journal-title":"PLoS One"},{"key":"422_CR5","unstructured":"World Health Organization. 2018.\u00a0https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death. Accessed 9 July 2020."},{"key":"422_CR6","first-page":"188","volume":"34","author":"O Holas","year":"2009","unstructured":"Holas O, Ezzo D. Nebivolol (bystolic), a novel beta blocker for hypertension. Drug Forecast. 2009;34:188\u201392.","journal-title":"Drug Forecast"},{"key":"422_CR7","first-page":"1","volume":"9","author":"D Adeloye","year":"2014","unstructured":"Adeloye D, Basquill C. Estimating the prevalence and awareness rates of hypertension in Africa: a systematic analysis. PLoS One. 2014;9:1\u201317.","journal-title":"PLoS One"},{"key":"422_CR8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.cjca.2017.03.005","volume":"33","author":"AA Leung","year":"2017","unstructured":"Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, et al. Hypertension Canada. Hypertension Canada\u2019s 2017 guidelines for diagnosis, risk assessment, prevention and treatment of hypertension in adults. Can J Cardiol. 2017;33:557\u201376.","journal-title":"Can J Cardiol"},{"key":"422_CR9","first-page":"1","volume":"12","author":"J Ahn","year":"2017","unstructured":"Ahn J, Kim HJ, Choi JI, Lee KN, Shim J, Ahn HS, et al. Effectiveness of beta-blockers depending on the genotype of congenital long-QT syndrome: a meta-analysis. PLoS One. 2017;12:1\u201313.","journal-title":"PLoS One"},{"key":"422_CR10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/clc.20249","volume":"31","author":"SG Chrysant","year":"2008","unstructured":"Chrysant SG, Chrysant GS, Dimas B. Current and future status of beta-blockers in the treatment of hypertension. Clin Cardiol. 2008;31:249\u201352.","journal-title":"Clin Cardiol"},{"key":"422_CR11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/5584_2016_36","volume":"956","author":"JM Cruikshank","year":"2017","unstructured":"Cruikshank JM. The role of beta-blockers in the treatment of hypertension. Adv Exp Med Biol. 2017;956:149\u201366.","journal-title":"Adv Exp Med Biol"},{"key":"422_CR12","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.amjcard.2009.12.068","volume":"105","author":"AR De Caterina","year":"2010","unstructured":"De Caterina AR, Leone AM. Why beta-blockers should not be used as first choice in uncomplicated hypertension. Am J Cardiol. 2010;105:1433\u20138.","journal-title":"Am J Cardiol"},{"key":"422_CR13","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.hlc.2016.07.018","volume":"26","author":"JR Richard","year":"2017","unstructured":"Richard JR. Beta blockers and the cardiac complications of methamphetamine. Heart Lung Circ. 2017;26:416\u20137.","journal-title":"Heart Lung Circ"},{"key":"422_CR14","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1016\/j.jacc.2017.04.017","volume":"69","author":"B Ibanez","year":"2017","unstructured":"Ibanez B, Raposeiras-Roubin S, Garcia-Ruiz JM. The swing of beta-blockers: time for a system reboot. J Am Coll Cardiol. 2017;69:2721\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"422_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11906-015-0580-y","volume":"17","author":"V Bell","year":"2015","unstructured":"Bell V, Mitchell GF. Influence of vascular function and pulsatile hemodynamics on cardiac function. Curr Hypertens Rep. 2015;17:1\u20139.","journal-title":"Curr Hypertens Rep"},{"key":"422_CR16","first-page":"909","volume":"3","author":"J Cockcroft","year":"2007","unstructured":"Cockcroft J. A review of the safety and efficacy of nebivolol in the mildly hypertensive patient. Vasc Health Risk Manag. 2007;3:909\u201317.","journal-title":"Vasc Health Risk Manag"},{"key":"422_CR17","first-page":"2","volume":"13","author":"LB George","year":"2007","unstructured":"George LB, Jerome DC, Edgar RG. The changing landscape of hypertension and the evolving role of vasodilatory beta-blockers. J Manag Care Pharm. 2007;13:2\u201324.","journal-title":"J Manag Care Pharm"},{"key":"422_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11906-017-0716-3","volume":"19","author":"M Marketou","year":"2017","unstructured":"Marketou M, Gupta Y, Jain S, Vardas P. Differential metabolic effects of beta-blockers: an updated systematic review of nebivolol. Curr Hypertens Rep. 2017;19:1\u201310.","journal-title":"Curr Hypertens Rep"},{"key":"422_CR19","volume-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Copenhagen: The Cochrane Collaboration; 2011."},{"key":"422_CR20","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336\u201341.","journal-title":"Int J Surg"},{"key":"422_CR21","volume-title":"Development and evaluation of a system for the characterization of clinical pharmaceutical services: DEPICT project","author":"I Rotta","year":"2015","unstructured":"Rotta I. Development and evaluation of a system for the characterization of clinical pharmaceutical services: DEPICT project. Curitiba: Clinics Hospital Library\u2019s from Parana Federal\u2019s University; 2015."},{"key":"422_CR22","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1038\/s41598-017-05759-2","volume":"7","author":"F Ursini","year":"2017","unstructured":"Ursini F, Leporini C, Bene F, D\u2019Angelo S, Mauro D, Russo E, et al. Anti-TNF-alpha agents and endothelial function in rheumatoid arthritis: a systematic review and meta-analysis. Sci Rep. 2017;7:5346.","journal-title":"Sci Rep"},{"key":"422_CR23","volume-title":"Comparative efficacy and safety of the use of topical antifungal agents in the treatment of dermatomycosis\u2014meta-analysis of randomized clinical trials","author":"I Rotta","year":"2011","unstructured":"Rotta I. Comparative efficacy and safety of the use of topical antifungal agents in the treatment of dermatomycosis\u2014meta-analysis of randomized clinical trials. Curitiba: Clinics Hospital Library\u2019s from Parana Federal\u2019s University; 2011."},{"key":"422_CR24","doi-asserted-by":"crossref","DOI":"10.1002\/9780470743386","volume-title":"Introduction to meta-analysis","author":"M Borenstein","year":"2009","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. Hoboken: Wiley; 2009."},{"key":"422_CR25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00044011-200222030-00007","volume":"22","author":"RW Dal Negro","year":"2002","unstructured":"Dal Negro RW, Tognella S, Mechelleto C. Pharmacokinetics of the effect of nebivolol 5\u00a0mg on airway patency in patients with mild to moderate bronchial asthma and arterial hypertension: a randomized, placebo-controlled study. Clin Drug Investig. 2002;22:197\u2013204.","journal-title":"Clin Drug Investig"},{"key":"422_CR26","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00044011-200222060-00003","volume":"22","author":"RW Dal Negro","year":"2002","unstructured":"Dal Negro RW, Tognella S, Pomari C. Once-daily nebivolol 5\u00a0mg does not reduce airway patency in patients with chronic obstructive pulmonary disease and arterial hypertension. Clin Drug Investig. 2002;22:361\u20137.","journal-title":"Clin Drug Investig"},{"key":"422_CR27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/HJH.0b013e3282f283c9","volume":"26","author":"YZ Dhakam","year":"2008","unstructured":"Dhakam YZ, McEniery CM, Burton T, Brown MJ, Wilkinson IBA. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008;26:351\u20136.","journal-title":"J Hypertens"},{"key":"422_CR28","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.1002\/clc.20508","volume":"33","author":"M Greathouse","year":"2010","unstructured":"Greathouse M. Nebivolol efficacy and safety in patients with stage I\u2013II hypertension. Clin Cardiol. 2010;33:E20\u20137.","journal-title":"Clin Cardiol"},{"key":"422_CR29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/jhh.2009.33","volume":"24","author":"JM Neutel","year":"2010","unstructured":"Neutel JM, Smith DHG, Gradman AH. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I\u2013II hypertension. J Hum Hypertens. 2010;24:64\u201373.","journal-title":"J Hum Hypertens"},{"key":"422_CR30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/1753944710387629","volume":"4","author":"H Punzi","year":"2010","unstructured":"Punzi H, Lewin A, Luk\u00edc T, Goodin T, Chen W. Efficacy and safety of nebivolol in Hispanics with stage I-II hypertension: a randomized placebo-controlled trial. Ther Adv Cardiovasc Dis. 2010;4:349\u201357.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"422_CR31","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/j.1524-6175.2007.07548.x","volume":"9","author":"E Saunders","year":"2007","unstructured":"Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens. 2007;9:866\u201375.","journal-title":"J Clin Hypertens"},{"key":"422_CR32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40256-013-0010-y","volume":"13","author":"RJ Weiss","year":"2013","unstructured":"Weiss RJ, Stapff M, Lin Y. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial. Am J Cardiovasc Drugs. 2013;13:129\u201340.","journal-title":"Am J Cardiovasc Drugs"},{"key":"422_CR33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1524-6175.2007.06679.x","volume":"9","author":"RJ Weiss","year":"2007","unstructured":"Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel beta-blocker, in patients with mild to moderate hypertension. J Clin Hypertens. 2007;9:667\u201376.","journal-title":"J Clin Hypertens"},{"key":"422_CR34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jch.12071","volume":"15","author":"P Deedwania","year":"2013","unstructured":"Deedwania P, Shea J, Chen W, Brener L. Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes. J Clin Hypertens. 2013;15:270\u20138.","journal-title":"J Clin Hypertens"},{"key":"422_CR35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jch.12169","volume":"15","author":"TD Giles","year":"2013","unstructured":"Giles TD, Khan BV, Lato J, Brener L, Ma Y, Lukic T. Nebivolol monotherapy in younger adults (younger than 55\u00a0years) with hypertension: a randomized, placebo-controlled trial. J Clin Hypertens. 2013;15:687\u201393.","journal-title":"J Clin Hypertens"},{"key":"422_CR36","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clinthera.2012.12.015","volume":"35","author":"A Lewin","year":"2013","unstructured":"Lewin A, Punzy H, Luo X, Stapff M. Nebivolol monotherapy for patients with systolic stage II Hypertension: results of randomized, placebo-controlled trial. Clin Ther. 2013;35:142\u201352.","journal-title":"Clin Ther"},{"key":"422_CR37","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/HYPERTENSIONAHA.111.189381","volume":"59","author":"AJ Stears","year":"2012","unstructured":"Stears AJ, Woods SH, Watts MM, Burton TJ, Graggaber J, Mir FA, et al. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension. 2012;59:934\u201342.","journal-title":"Hypertension"},{"key":"422_CR38","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1751-7176.2012.00666.x","volume":"14","author":"MA Weber","year":"2012","unstructured":"Weber MA, Basile J, Stapff M, Khan B, Zhou D. Blood pressure effects of combined beta-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: a placebo-controlled study with nebivolol and lisinopril. J Clin Hypertens. 2012;14:588\u201392.","journal-title":"J Clin Hypertens"},{"key":"422_CR39","doi-asserted-by":"crossref","first-page":"HCO1","DOI":"10.1111\/crj.12028","volume":"8","author":"VV Bhosale","year":"2014","unstructured":"Bhosale VV, Inamdar SC, Karande VB, Burute SR, Murthy MB, Ghatak A. Beneficial effects of nebivolol in comparison with atenolol with atenolol on safety and tolerability in essential hypertension. J Clin Diagn Res. 2014;8:HCO1\u20134.","journal-title":"J Clin Diagn Res"},{"key":"422_CR40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/08038020310023271","volume":"12","author":"G Grassi","year":"2003","unstructured":"Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicenter trial. Blood Press Suppl. 2003;12:35\u201340.","journal-title":"Blood Press Suppl"},{"key":"422_CR41","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0002-9149(03)00645-3","volume":"92","author":"O Kamp","year":"2003","unstructured":"Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003;92:344\u20138.","journal-title":"Am J Cardiol"},{"key":"422_CR42","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/01.hjh.0000160216.86597.ff","volume":"23","author":"AF Pasini","year":"2005","unstructured":"Pasini AF, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens. 2005;23:589\u201396.","journal-title":"J Hypertens"},{"key":"422_CR43","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/ajh.2008.260","volume":"21","author":"AF Pasini","year":"2008","unstructured":"Pasini AF, Garbin U, Stranieri C, Boccioletti V, Mozzini C, Manfro S, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens. 2008;21:1251\u20137.","journal-title":"Am J Hypertens"},{"key":"422_CR44","first-page":"334","volume":"4","author":"V Susmitha","year":"2013","unstructured":"Susmitha V, Naganjani CV. Comparative study of nebivolol versus atenolol in the treatment of mild and moderate essential hypertension. Int J Pharm Bio Sci. 2013;4:334\u20138.","journal-title":"Int J Pharm Bio Sci"},{"key":"422_CR45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1161\/HYPERTENSIONAHA.110.169169","volume":"58","author":"C Espinola-Klein","year":"2011","unstructured":"Espinola-Klein C, Weisser G, Jagodzinski A, Savvidis S, Warnholtz A, Ostad MA, et al. Beta-blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. 2011;58:148\u201354.","journal-title":"Hypertension"},{"key":"422_CR46","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/FJC.0b013e31829f716a","volume":"62","author":"F Fici","year":"2013","unstructured":"Fici F, Celik T, Balta S, Iyisoy A, Unlu M, Demitkol S, et al. Comparative effects of nebivolol and metoprolol on red cell distribution width and neutrophil\/lymphocyte ratio in patients with newly diagnosed essential hypertension. J Cardiovasc Pharmacol. 2013;62:388\u201393.","journal-title":"J Cardiovasc Pharmacol"},{"key":"422_CR47","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jash.2014.12.013","volume":"9","author":"SS Hayek","year":"2015","unstructured":"Hayek SS, Poole JC, Neuman R, Morris AA, Khayata M, Kavtaradze N, et al. Differential effects of nebivolol and metoprolol on arterial stiffness, circulating progenitor cells, and oxidative stress. J Am Soc Hypertens. 2015;9:206\u201313.","journal-title":"J Am Soc Hypertens"},{"key":"422_CR48","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1161\/HYPERTENSIONAHA.110.155507","volume":"57","author":"P Kampus","year":"2011","unstructured":"Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57:1122\u20138.","journal-title":"Hypertension"},{"key":"422_CR49","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00059-012-3695-9","volume":"38","author":"MR Sayin","year":"2012","unstructured":"Sayin MR, Aydin M, Dogan SM, Karabag T, Cetiner MA, Aktop Z. Aortic elastic properties: effects of carvedilol versus nebivolol. Herz. 2012;38:299\u2013305.","journal-title":"Herz"},{"key":"422_CR50","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3109\/00365513.2012.691991","volume":"72","author":"M Serg","year":"2012","unstructured":"Serg M, Kampus P, Kals J, Zagura M, Zilmer M, Zilmer K, et al. Nebivolol and metoprolol: long-term effects on inflammation and oxidative stress in essential hypertension. Scand J Clin Lab Investig. 2012;72:427\u201332.","journal-title":"Scand J Clin Lab Investig"},{"key":"422_CR51","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1185\/03007995.2010.497326","volume":"26","author":"J Heitmann","year":"2010","unstructured":"Heitmann J, Greulich T, Reinke C, Koehler U, Vogelmeier C, Becker HF, et al. Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnea activity in patients with essential hypertension and OSA. Curr Med Res Opin. 2010;26:1925\u201332.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"422_CR52","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jash.2015.03.009","volume":"9","author":"JL Izzo","year":"2015","unstructured":"Izzo JL, Khan SU, Saleem O, Osmond PJ. Ambulatory 24-hour cardiac oxygen consumption and blood pressure-heart rate variability: effects of nebivolol and valsartan alone and in combination. J Am Soc Hypertens. 2015;9(7):526\u201335.","journal-title":"J Am Soc Hypertens"},{"key":"422_CR53","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjhyper.2005.03.733","volume":"18","author":"LM Van Bortel","year":"2005","unstructured":"Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens. 2005;18:1060\u20136.","journal-title":"Am J Hypertens"},{"key":"422_CR54","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1097\/HJH.0b013e3283471151","volume":"29","author":"C Diehm","year":"2011","unstructured":"Diehm C, Pittrow D, Lawall H. Effect of nebivolol vs. hydrochrolothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens. 2011;29:1448\u201356.","journal-title":"J Hypertens"},{"key":"422_CR55","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/S0140-6736(14)60614-0","volume":"383","author":"TD Giles","year":"2014","unstructured":"Giles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, NAC-MD-01 Study Investigators, et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomized, multicenter study. Lancet. 2014;383:1889\u201398.","journal-title":"Lancet"},{"key":"422_CR56","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/j.1552-4604.1992.tb05778.x","volume":"32","author":"Y Lacourciere","year":"1992","unstructured":"Lacourciere Y, Poirier L, Lefebvre J, Provencher P, Arnott W. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol. 1992;32:660\u20136.","journal-title":"J Clin Pharmacol"},{"key":"422_CR57","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1097\/00004872-198900076-00127","volume":"7","author":"T van Merode","year":"1989","unstructured":"van Merode T, van Bortel LM, Smeets FA, Mooij JM, Bohm RO, Rahn KH, et al. Verapamil and nebivolol improve carotid artery distensibility in hypertensive patients. J Hypertens. 1989;7:S262\u20133.","journal-title":"J Hypertens"},{"key":"422_CR58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/08038020310000104","volume":"1","author":"EA Rosei","year":"2003","unstructured":"Rosei EA, Rizzoni D, Comini S, Boari G, Nebivolol-Lisinopril Study Group. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicenter, double-blind study. Blood Press Suppl. 2003;1:30\u20135.","journal-title":"Blood Press Suppl."},{"key":"422_CR59","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jama.279.23.1903","volume":"279","author":"FH Messerli","year":"1998","unstructured":"Messerli FH, Grossman E, Glodbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA. 1998;279:903\u20137.","journal-title":"JAMA"},{"key":"422_CR60","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/j.cjca.2014.02.012","volume":"30","author":"P Larochelle","year":"2014","unstructured":"Larochelle P, Tobe SW, Lacourciere Y. Beta-blocker in hypertension: studies and meta-analysis over the years. Can J Cardiol. 2014;30:S16\u201322.","journal-title":"Can J Cardiol"},{"key":"422_CR61","doi-asserted-by":"crossref","unstructured":"Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Mbewu A, Opie LH. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2012;(11):CD002003.","DOI":"10.1002\/14651858.CD002003.pub3"},{"key":"422_CR62","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1503\/cmaj.060110","volume":"174","author":"N Khan","year":"2006","unstructured":"Khan N, Mcalister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174:1737\u201342.","journal-title":"CMAJ"},{"key":"422_CR63","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1136\/bmj.b1665","volume":"338","author":"MR Law","year":"2009","unstructured":"Law MR, Morris JK, Wald DS. Use of blood pressure-lowering drugs in the prevention of cardiovascular disease: meta-analysis of randomized trials in the context of expectations from prospective epidemiological studies. BJM. 2009;338:1665\u201384.","journal-title":"BJM"},{"key":"422_CR64","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.phrs.2006.12.008","volume":"55","author":"S Evangelista","year":"2007","unstructured":"Evangelista S, Garbin U, Pasini AF, Stranieri C, Boccioletti V, Cominacini L. Effect of dl-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res. 2007;55:303\u20139.","journal-title":"Pharmacol Res"},{"issue":"S1","key":"422_CR65","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF03258273","volume":"3","author":"O Uhl\u00ed\u0159","year":"1991","unstructured":"Uhl\u00ed\u0159 O, Fejfu\u0161a M, Havr\u00e1nek K, Lefflerov\u00e1 K, Voj\u00e1\u010dek J, Widimsk\u00fd J, Winterov\u00e1 J, Zeman K. Nebivolol Versus Metoprolol in the Treatment of Hypertension. Drug Investigation. 1991;3(S1):107\u201310.","journal-title":"Drug Investigation"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00422-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-020-00422-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00422-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T19:38:59Z","timestamp":1723318739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-020-00422-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,25]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["422"],"URL":"https:\/\/doi.org\/10.1007\/s40256-020-00422-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,25]]},"assertion":[{"value":"25 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Vin\u00edcius Bocchino Seleme, Gustavo Lenci Marques, Antonio Eduardo Matoso Mendes, Inajara Rotta, Milena Pereira, Emilton Lima J\u00fanior, and Claudio L. Pereira da Cunha declare they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with humans or animals subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}